Back to Cetuximab

Cetuximab

Showing 8 study arms with grade ≥3 adverse event data (treatment-related and RT-related). Click a column header to sort.

Note on patient counts: some articles reported only percentages rather than absolute numbers. Where this occurred, the number of patients — including those with grade ≥3 adverse events — was derived by applying the reported percentage to the total arm size, which may produce a non-integer value. These figures have been rounded to the nearest integer for display.

1st Author⇅	Year⇅	Study Type⇅	Title⇅	DOI⇅	clinical trial number⇅	number of patients⇅	median/mean age⇅	median follow-up [months]⇅	tumor type⇅	treatment setting⇅	drug group⇅	drug name⇅	if other, please specify⇅	number of SBRT courses⇅	intracranial / extracranial⇅	treated site⇅	If other treated site, please specify⇅	median/mean total RT dose [Gy]⇅	minimum total RT dose [Gy]⇅	maximum total RT dose [Gy]⇅	median/mean number of fractions⇅	minimum number of fractions⇅	maximum number of fractions⇅	median/mean dose per fraction [Gy]⇅	minimum dose per fraction [Gy]⇅	maximum dose per fraction [Gy]⇅	toxicity type⇅	patients with acute G>=3 toxicity⇅	patients with late G>=3 toxicity⇅	patients with G>=3 toxicity, timing unspecified⇅	G>=3 AEs⇅	patients with G>=3 AEs⇅	details on G>=3 toxicity⇅	details on G>=3 toxicity in RT field⇅
Looman et al.	2026	Prospective	Adverse Events After Metastases-Directed Stereotactic Radiotherapy and Biological Cancer Therapy	10.1001/jamanetworkopen.2025.53809	—	2	62	18	Breast cancer, Lung cancer, Prostate cancer, Colorectal cancer, Head and neck cancer, Esophagus cancer, Melanoma, Kidney cancer, Bladder cancer, Sarcoma, other	oligometastatic, metastatic	Anti-EGFR mAb	Cetuximab	—	Missing	extra-cranial	lung	—	—	—	—	Missing	1	10	—	—	—	RT-related	—	—	0	—	—	—	—
Looman et al.	2026	Prospective	Adverse Events After Metastases-Directed Stereotactic Radiotherapy and Biological Cancer Therapy	10.1001/jamanetworkopen.2025.53809	—	1	62	18	Breast cancer, Lung cancer, Prostate cancer, Colorectal cancer, Head and neck cancer, Esophagus cancer, Melanoma, Kidney cancer, Bladder cancer, Sarcoma, other	oligometastatic, metastatic	Anti-EGFR mAb	Cetuximab	—	Missing	extra-cranial	other	Abdomen	—	—	—	Missing	1	10	—	—	—	RT-related	—	—	0	—	—	—	—
Huang et al.	2022	Retrospective	Stereotactic body radiotherapy plus cetuximab for previously irradiated un-resectable head and neck cancer	10.1016/j.bj.2021.10.013	—	74	58	9	Head and neck cancer	metastatic	Anti-EGFR mAb	Cetuximab	—	74	extra-cranial	cervical lymph nodes	primary head and neck tumor	40	40.0	50.0	5	5	5	8	8	10	RT-related	13	15	—	acute G3: 13 AEs, late G>=3: 15 AEs	acute G3: 13 pts, late G>=3: 15 pts	acute G3: mucositis, radiation dermatitis, late G>=3: dysphagia and/or laryngeal edema, osteonecrosis or soft tissue necrosis, carotid blowout.	acute G3: mucositis, radiation dermatitis, late G>=3: dysphagia and/or laryngeal edema, osteonecrosis or soft tissue necrosis, carotid blowout.
Gebhardt et al.	2018	Retrospective	Carotid Dosimetry and the Risk of Carotid Blowout Syndrome After Reirradiation With Head and Neck Stereotactic Body Radiation Therapy	10.1016/j.ijrobp.2017.11.045	—	63	65	8	Head and neck cancer	any	Anti-EGFR mAb	Cetuximab	—	Missing	extra-cranial	other	head and neck	44	40.0	50.0	5	5	5	8.8	8	10	RT-related	0	4	—	late G3-4: 2 AEs, late G5: 2 AEs	late G3-4: 2 pts, late G5: 2 pts	late G3-4: carotid bleeding, late G5: carotid blowout syndrome	late G3-4: carotid bleeding, late G5: carotid blowout syndrome
Quan et al.	2016	Retrospective	Toxicities Following Stereotactic Ablative Radiotherapy Treatment of Locally-Recurrent and Previously Irradiated Head and Neck Squamous Cell Carcinoma	10.1016/j.semradonc.2015.11.007	—	18	64	Missing	Head and neck cancer	primary	Anti-EGFR mAb	Cetuximab	—	18	extra-cranial	other	recurrent head and neck tumor	40	40.0	44.0	5	5	5	8	8	8, 8	Treatment-rel.	—	—	1	any G3: 2 AEs	any G3: 1 pt	any G3: mucositis, rash (erbitux)	any G3: mucositis
Vargo et al.	2015	Prospective	A prospective phase 2 trial of reirradiation with stereotactic body radiation therapy plus cetuximab in patients with previously irradiated recurrent squamous cell carcinoma of the head and neck	10.1016/j.ijrobp.2014.11.023	NCT 01104922	48	63	18	Head and neck cancer	primary	Anti-EGFR mAb	Cetuximab	—	48	extra-cranial	other	recurrent head and neck tumor	Missing	40.0	44.0	5	5	5	Missing	8	8.8	Treatment-rel.	3	3	—	acute G3: 4 AEs, late G3: 3 AEs	acute G3: 3 pts, late G3: 3 pts	acute G3: mucositis/skin, dysphagia, skin, late G3: dypshagia, aerodigestive fistula	acute G3: mucositis/skin, dysphagia, skin, late G3: dypshagia, aerodigestive fistula
Vargo et al.	2014	Retrospective	Examining tumor control and toxicity after stereotactic body radiotherapy in locally recurrent previously irradiated head and neck cancers: implications of treatment duration and tumor volume	10.1002/hed.23462	—	132	66	6	Head and neck cancer	any	Anti-EGFR mAb	Cetuximab	—	Missing	extra-cranial	other, cervical lymph nodes	head and neck	44	35.0	50.0	5	5	5	Missing	Missing	Missing	Treatment-rel.	16	6	—	acute G3-4: 19 AEs, late G3: 6 AEs	acute G3-4: 16 pts, late G3: 6 pts	acute G3-4: Mucositis, dysphagia, skin reactions, xerostomia, dysgeusia, pain, fatigue, late G3: Dysphagia, skin reactions, pain, osteonecrosis	—
Lartigau et al.	2013	Prospective	Multi institutional phase II study of concomitant stereotactic reirradiation and cetuximab for recurrent head and neck cancer	10.1016/j.radonc.2013.08.012	Missing	56	60	11.4	Head and neck cancer	primary	Anti-EGFR mAb	Cetuximab	—	56	extra-cranial	other	head and neck	36	36.0	36.0	6	6	6	6	6	6	Treatment-rel.	—	—	19	any G3: 18 AEs, any G5: 1 AE	any G3: 18 pts, any G5: 1 pt	any G3: mucositis, cutaneous toxicity, rash, fibrosis, dysphagia, xerostomia, fistula, dysgeusia, any G5: hemorrhage and denutrition	unknown